Clinical Trial Search

Phase 3 N=302 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Chronic Hepatitis C Virus (HCV) Infection

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN…

AbbVie Results Sep 2017 1.2% serious AE View details

Phase 3 N=141 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Chronic Hepatitis C · Hepatitis C Virus · HCV

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 95.5; 86.4; 88.6 percentage of participants

AbbVie Results Sep 2017 3.6% serious AE View details

Phase 3 N=42 Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

Post-surgical Cystoid Macular Edema (PSCME)

Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters

Johns Hopkins University Results Sep 2017 21.4% serious AE View details

Phase 3 N=179 Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Diabetes Mellitus, Type 1

Primary: Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12 — -0.14; -0.23 nanomoles per…

GlaxoSmithKline Results Sep 2017 8.4% serious AE View details

Phase 3 N=77 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

HIV · HIV Infections · Pregnancy

Primary: Predose (Trough) Plasma Concentration (C0h) — 3608; 491.4; 2481; 147 nanogram per milliliter (ng/mL)

Janssen Scientific Affairs, LLC Results Sep 2017 27.3% serious AE View details

Phase 3 N=42 Comparing Ways to Freeze the Nerve That Provides Thigh Sensation

Meralgia Paresthetica

Primary: Anesthesia Related Time — 554; 480 seconds — p=0.05

Canadian Forces Health Services Centre Ottawa Results Sep 2017 0.0% serious AE View details

Phase 3 N=407 Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

Contraception

Primary: Pregnancy Reported as Pearl Index — 8.19; 6.80 Pearl Index

Agile Therapeutics Results Sep 2017 0.5% serious AE View details

Phase 3 N=506 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

Chronic Hepatitis C · Hepatitis C Virus · Genotype 3 Hepatitis C Virus

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm A to Arm B — 95.3; 96.5 percentage of participants

AbbVie Results Sep 2017 2.0% serious AE View details

Phase 3 N=394 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Psoriatic Arthritis

Primary: Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 — 49.62; 46.97; 23.66 Percentage…

Pfizer Results Sep 2017 4.1% serious AE View details

Phase 3 N=121 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

Hepatitis C Virus

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.2 percentage of participants

AbbVie Results Sep 2017 0.8% serious AE View details

Phase 3 N=703 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C · Hepatitis C Virus · HCV

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Mono-infected Hepatitis C Virus Genotype 1 (HCV GT1), Direct-acting…

AbbVie Results Sep 2017 1.3% serious AE View details

Phase 3 N=559 A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

Arthritis, Rheumatoid

Primary: Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24 — 6.89; 6.90; 6.91; -2.19 units on a scale — p=< 0.001

Janssen Research & Development, LLC Results Sep 2017 12.0% serious AE View details

Phase 3 N=4,007 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Measles-Mumps-Rubella

Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 697; 249; 736; 281 Participants

GlaxoSmithKline Results Sep 2017 1.3% serious AE View details

Phase 3 N=110 A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

Parkinson's Disease

Primary: Percentage of "OFF" Time During Waking Hours — 23.98; 32.48 Percent

Impax Laboratories, LLC Results Sep 2017 1.1% serious AE View details

Phase 3 N=444 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -0.23; -0.82; -0.85 % of hemoglobin — p=<0.0001

AstraZeneca Results Sep 2017 2.7% serious AE View details